PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer
Cheng Wu(Second Military Medical University), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center), Shakuntala Kondraganti(University of Illinois Urbana-Champaign), Bradley M. Broom(The University of Texas MD Anderson Cancer Center), Patrick G. Pilié(The University of Texas MD Anderson Cancer Center), Jonathan L. Curry(The University of Texas MD Anderson Cancer Center), Yungang Lu(The University of Texas MD Anderson Cancer Center), Carlos A. Torres‐Cabala(The University of Texas MD Anderson Cancer Center), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Debora Alejandra Ledesma(The University of Texas MD Anderson Cancer Center), Paul G. Corn(Cornell University), Mario L. Marques‐Piubelli(The University of Texas MD Anderson Cancer Center), Guang Yang(Jinan University), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Sanghee Park(Hanbat National University), Zhe Tang(Zhejiang International Studies University), Shan Peng(The University of Texas MD Anderson Cancer Center), Daoqi Wang(The University of Texas MD Anderson Cancer Center), Chuandong Geng(Baylor College of Medicine), Courtney W. Hudgens(The University of Texas MD Anderson Cancer Center)
Cited by 58
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
|Cell|2016|2.4k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k